natgillin/translations-raw huggingface dataset:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deferasirox Mylan have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Deferasirox Mylan upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
It attaches to excess iron in the body to form a compound called a ‘chelate' that can be removed by the body, mainly in the stool. 
Veže se na odvečno železo v telesu in tvori „kelat“, ki ga telo lahko izloči, in sicer pretežno z blatom.
The company that markets Deferasirox Mylan must issue an education pack to healthcare professionals. 
Podjetje, ki izdeluje zdravilo Deferasirox Mylan, mora izdati izobraževalno gradivo za zdravstvene delavce.
Side effects reported with Deferasirox Mylan are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Deferasirox Mylan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
This pack aims to inform them about the treatment recommendations with Deferasirox Mylan, including choosing the right dose and the need to monitor the patient's health, especially kidney function. 
Gradivo jih bo seznanilo o priporočilih glede zdravljenja z zdravilom Deferasirox Mylan, med drugim o izbiri pravilnega odmerka in potrebi po spremljanju zdravja bolnika, zlasti delovanja ledvic.
For more information about using Deferasirox Mylan, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Deferasirox Mylan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As for all medicines, data on the use of Deferasirox Mylan are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Deferasirox Mylan stalno spremljajo.
Non-transfusion-dependent thalassaemia syndromes are blood disorders similar to beta thalassaemia major but which do not require blood transfusions. 
Sindromi od transfuzije neodvisne talasemije so krvna obolenja, podobna beta talasemiji major, le da pri njih transfuzije krvi niso potrebne.
Deferasirox Mylan is a medicine used to treat chronic iron overload (an excess of iron in the body) in: 
Deferasirox Mylan je zdravilo, ki se uporablja za zdravljenje kronične preobremenitve z železom (prevelike količine železa v krvi) pri:
An overview of Deferasirox Mylan and why it is authorised in the EU 
Pregled zdravila Deferasirox Mylan in zakaj je odobreno v EU
This means that Deferasirox Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Exjade. 
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Exjade.
What are the benefits and risks of Deferasirox Mylan? 
Kakšne so koristi in tveganja zdravila Deferasirox Mylan?
Deferasirox Mylan can only be obtained with a prescription and treatment should be started and supervised by a doctor who is experienced in the treatment of chronic iron overload. 
Predpisovanje in izdaja zdravila Deferasirox Mylan je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem kronične preobremenitve z železom.
Other information about Deferasirox Mylan 
Druge informacije o zdravilu Deferasirox Mylan
• patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin - the protein that carries oxygen around the body - in the blood) and who receive frequent blood transfusions; 
• bolnikih od šestega leta starosti dalje, ki imajo beta talasemijo major (dedno krvno bolezen, pri kateri bolniki nimajo dovolj normalnega hemoglobina, tj. beljakovine, ki prenaša kisik po telesu, v krvi) in ki prejemajo pogoste transfuzije krvi;
Why is Deferasirox Mylan authorised in the EU? 
Zakaj je bilo zdravilo Deferasirox Mylan odobreno v EU?
What is Deferasirox Mylan and what is it used for? 
Kaj je zdravilo Deferasirox Mylan in za kaj se uporablja?
The active substance in Deferasirox Mylan, deferasirox, is an ‘iron chelator'. 
Učinkovina v zdravilu Deferasirox Mylan, deferasiroks, je „kelator železa“.
Deferasirox Mylan contains the active substance deferasirox and is a ‘generic medicine'. 
Zdravilo Deferasirox Mylan vsebuje učinkovino deferasiroks in je „generično zdravilo“.
The starting dose of Deferasirox Mylan depends on the patient's body weight, what the medicine is used for, and on the level of iron overload. 
Začetni odmerek zdravila Deferasirox Mylan je odvisen od telesne mase bolnika, namena uporabe zdravila in ravni preobremenitve z železom.
• children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate; 
• otrocih v starosti od dveh do petih let z beta talasemijo major, ki pogosto prejemajo transfuzije krvi, kadar deferoksamina (drugega zdravila, ki se uporablja za zdravljenje preobremenitve z železom) ni mogoče uporabljati ali ta ni ustrezen;
Therefore, the Agency's view was that, as for Exjade, the benefits of Deferasirox Mylan outweigh the identified risks and it can be authorised for use in the EU. 
Zato je agencija menila, da koristi zdravila Deferasirox Mylan enako kot pri zdravilu Exjade odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
• patients from 2 years of age who suffer from other types of anaemia (low levels of haemoglobin in the blood) and who receive blood transfusions, when deferoxamine cannot be used or is inadequate; 
• bolnikih od drugega leta starosti dalje, ki imajo različne oblike slabokrvnosti (nizke ravni hemoglobina v krvi) in prejemajo transfuzije krvi, kadar deferoksamina ni mogoče uporabljati ali ta ni ustrezen;
How has Deferasirox Mylan been studied? 
Kako je bilo zdravilo Deferasirox Mylan raziskano?
• patients from 10 years of age with non-transfusion-dependent thalassaemia syndromes, when deferoxamine cannot be used or is inadequate. 
• bolnikih od desetega leta starosti dalje s sindromi od transfuzije neodvisne talasemije, kadar deferoksamina ni mogoče uporabljati ali ta ni ustrezen.
How is Deferasirox Mylan used? 
Kako se zdravilo Deferasirox Mylan uporablja?
• patients from 2 years of age with beta thalassaemia major who receive infrequent blood transfusions, when deferoxamine cannot be used or is inadequate; 
• bolnikih z beta talasemijo major od drugega leta starosti dalje, ki transfuzije krvi ne prejemajo redno, kadar deferoksamina ni mogoče uporabljati ali ta ni ustrezen;
How does Deferasirox Mylan work? 
Kako zdravilo Deferasirox Mylan deluje?
Further information on Trydonis can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis. 
Nadaljnje informacije o zdravilu Trydonis so na voljo na spletni strani agencije: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis.
What measures are being taken to ensure the safe and effective use of Trydonis? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trydonis?
Trydonis received a marketing authorisation valid throughout the EU on 26 April 2018. 
Za zdravilo Trydonis je bilo 26. aprila 2018 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
The European Medicines Agency therefore decided that Trydonis's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Trydonis večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Trydonis 
Druge informacije o zdravilu Trydonis
As for all medicines, data on the use of Trydonis is continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Trydonis stalno spremljajo.
What benefits of Trydonis have been shown in studies? 
Kakšne koristi je zdravilo Trydonis izkazalo v študijah?
For more information about using Trydonis, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Trydonis glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Why is Trydonis authorised in the EU? 
Zakaj je bilo zdravilo Trydonis odobreno v EU?
Side effects reported with Trydonis are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Trydonis, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The company that makes Trimbow has agreed that its scientific data can be used for Trydonis (‘informed consent'). 
Podjetje, ki proizvaja zdravilo Trimbow, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Trydonis („uporaba dokumentacije s soglasjem“).
Trydonis (beclometasone / formoterol / glycopyrronium bromide) 
Trydonis (beklometazon/formoterol/glikopironijev bromid)
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trydonis have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Trydonis upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is Trydonis and what is it used for? 
Kaj je zdravilo Trydonis in za kaj se uporablja?
What are the risks associated with Trydonis? 
Kakšna tveganja so povezana z zdravilom Trydonis?
An overview of Trydonis and why it is authorised in the EU 
Pregled zdravila Trydonis in zakaj je odobreno v EU
Trydonis is available as a liquid in a portable inhaler device. 
Zdravilo Trydonis je na voljo v obliki tekočine v prenosnem inhalatorju.
No major safety concerns have been reported with Trydonis, with side effects being manageable and similar to other COPD medicines. 
Glede zdravila Trydonis niso poročali o večjih varnostnih pomislekih, saj so neželeni učinki obvladljivi in podobni kot pri drugih zdravilih za zdravljenje KOPB.
Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs.. 
Agonisti adrenergičnih receptorjev beta-2 in antagonisti muskarinskih receptorjev pomagajo razširiti dihalne poti, kortikosteroidi pa zmanjšujejo vnetje v dihalnih poteh in pljučih.
In the first study lasting a year, after 26 weeks of treatment, Trydonis improved patients' FEV1 (the maximum volume of air a person can breathe out in one second) by 82 ml before a dose and 261 ml after a dose. 
V prvi študiji, ki je trajala eno leto, je zdravilo Trydonis po 26 tednih izboljšalo bolnikov FEV1 (največji volumen zraka, ki ga oseba lahko izdihne v eni sekundi) za 82 ml pred prejetim odmerkom in 261 ml po prejetem odmerku.
Side effects with Trydonis include oral candidiasis (a fungal infection of the mouth caused by a yeast called Candida), muscle spasms and dry mouth. 
Neželeni učinki zdravila Trydonis vključujejo oralno kandidiazo (glivično okužbo ust, ki jo povzroča kvasovka Candida), mišične krče in suha usta.
For the full list of side effects and restrictions with Trydonis, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Trydonis glejte navodilo za uporabo.
Trydonis is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist. 
Zdravilo Trydonis se uporablja za vzdrževalno (nadaljevalno) zdravljenje pri bolnikih, pri katerih bolezen ni ustrezno nadzorovana kljub zdravljenju s kombinacijo dveh zdravil za zdravljenje KOPB, sestavljenih iz dolgodelujočega agonista adrenergičnih receptorjev beta-2 in inhalacijskega kortikosteroida ali dolgodelujočega antagonista muskarinskih receptorjev.
Beclometasone belongs to anti-inflammatory medicines known as corticosteroids. 
Beklometazon spada med protivnetna zdravila, ki jih imenujemo kortikosteroidi.
Trydonis is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). 
Zdravilo Trydonis se uporablja za lajšanje simptomov zmerne do hude oblike kronične obstruktivne pljučne bolezni (KOPB) pri odraslih.
In the third study lasting a year, patients treated with Trydonis had 15% fewer exacerbations a year than patients treated with a combination of indacaterol (a long-acting beta-2 agonist) and glycopyrronium bromide. 
V tretji študiji, ki je trajala eno leto, so imeli bolniki, zdravljeni z zdravilom Trydonis, 15 % manj izbruhov bolezni na leto kot bolniki, zdravljeni s kombinacijo indakaterola (dolgodelujočega agonista receptorjev beta-2) in glikopironijevega bromida.
Trydonis is effective at reducing the frequency of exacerbations and improving lung function of patients with COPD. 
Zdravilo Trydonis je učinkovito pri zmanjševanju pogostnosti izbruhov in izboljševanju delovanja pljuč pri bolnikih s KOPB.
In this study, Trydonis was as effective as tiotropium plus a combination of beclometasone and formoterol at reducing the number of exacerbations. 
V tej študiji je bilo zdravilo Trydonis pri zmanjševanju števila izbruhov enako učinkovito kot tiotropij in kombinacija beklometazona in formoterola.
In the second study lasting a year, patients treated with Trydonis had 20% fewer exacerbations (flareups of symptoms) per year than patients treated with tiotropium (a long-acting muscarinic receptor antagonist). 
V drugi študiji, ki je trajala eno leto, so imeli bolniki, zdravljeni z zdravilom Trydonis, 20 % manj izbruhov bolezni (poslabšanj simptomov) na leto kot bolniki, zdravljeni s tiotropijem (dolgodelujočim antagonistom muskarinskih receptorjev).
How is Trydonis used? 
Kako se zdravilo Trydonis uporablja?
Trydonis contains the active substances beclometasone, formoterol and glycopyrronium bromide. 
Zdravilo Trydonis vsebuje učinkovine beklometazon, formoterol in glikopironijev bromid.
The three active substances in Trydonis work in different ways to reduce inflammation and keep the airways open, allowing the patient to breathe more easily. 
Tri učinkovine v zdravilu Trydonis na različne načine zmanjšujejo vnetje in ohranjajo prehodnost dihalnih poti, kar bolniku omogoča lažje dihanje.
How does Trydonis work? 
Kako zdravilo Trydonis deluje?
Trydonis has been shown to be effective at relieving symptoms of COPD in three main studies involving over 5,500 patients whose symptoms were not controlled well enough either by combinations of two other COPD medicines or by a muscarinic receptor antagonist alone. 
V treh glavnih študijah, ki so vključevale več kot 5 500 bolnikov, pri katerih simptomi s kombinacijo dveh drugih zdravil za zdravljenje KOPB ali samostojnim antagonistom muskarinskih receptorjev niso bili ustrezno nadzorovani, so dokazali, da je zdravilo Trydonis učinkovito pri lajšanju simptomov KOPB.
By comparison, the FEV1 increased by 1 and 145 ml before and after dosing in patients treated with a medicine containing only 2 of the active substances found in Trydonis (beclometasone plus formoterol). 
Za primerjavo se je pri bolnikih, zdravljenih z zdravilom, ki zajema le dve od učinkovin, ki jih vsebuje zdravilo Trydonis (beklometazon in formoterol), FEV1 izboljšal za 1 ml pred prejetim odmerkom in 145 ml po prejetem odmerku.
The infusion should last 30 minutes. 
Infundiranje traja 30 minut.
Two of the studies were designed to define the best dose to use. 
Dve študiji sta bili zasnovani za določitev najustreznejšega odmerka za uporabo.
The European Commission granted a marketing authorisation valid throughout the European Union for Fasturtec on 23 February 2001. 
Evropska komisija je dovoljenje za promet z zdravilom Fasturtec, veljavno po vsej Evropski uniji, odobrila dne 23. februarja 2001.
The full EPAR for Fasturtec can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Fasturtec je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about Fasturtec 
Druge informacije o zdravilu Fasturtec
Fasturtec was not compared with another medicine in this study. 
Zdravila Fasturtec v tej študiji niso primerjali z nobenim drugim zdravilom.
This is a summary of the European public assessment report (EPAR) for Fasturtec. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Fasturtec.
This study also showed improvement in kidney function. 
V tej študiji je bilo dokazano tudi izboljšanje delovanja ledvic.
For more information about treatment with Fasturtec, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Fasturtec preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What benefit has Fasturtec shown during the studies? 
Kakšne koristi je zdravilo Fasturtec izkazalo med študijami?
The benefits of Fasturtec were first studied in three main studies involving a total of 293 patients, including adults and children. 
Učinke zdravila Fasturtec so najprej proučevali v treh glavnih študijah, v katerih je skupno sodelovalo 293 bolnikov, vključno z odraslimi in otroci.
The CHMP decided that Fasturtec's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Fasturtec večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Uric acid is a by-product of the breakdown of cells. 
Sečna kislina je stranski produkt razgradnje celic.
Fasturtec treatment should be supervised by a doctor who has been trained in the use of chemotherapy for blood cancers. 
Zdravljenje z zdravilom Fasturtec mora nadzorovati zdravnik, ki je usposobljen za uporabo kemoterapije pri zdravljenju krvnega raka.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fasturtec. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Fasturtec is given immediately before or during the start of chemotherapy. 
Zdravilo Fasturtec se daje tik pred kemoterapijo ali na njenem začetku.
It is used in adults and children with blood cancers who are at risk of a sudden rise in uric acid levels when they start to receive chemotherapy (medicines to treat cancer). 
Uporablja se pri odraslih in otrocih s krvnim rakom, pri katerih obstaja tveganje za nenadno povečanje koncentracije sečne kisline, ko začnejo prejemati kemoterapijo (zdravila za zdravljenje raka).
The main measures of effectiveness were based on the reduction in blood uric acid levels. 
Glavna merila učinkovitosti so temeljila na znižanju koncentracije sečne kisline v krvi.
The most common side effects with Fasturtec (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, headache, fever and diarrhoea. 
Najpogostejši neželeni učinki zdravila Fasturtec (opaženi pri več kot 1 bolniku od 10) so navzeja (slabost), bruhanje, glavobol, povišana telesna temperatura in driska.
In the comparative study, Fasturtec was more effective than allopurinol: over the first 96 hours after treatment, patients treated with Fasturtec had a lower average blood level of uric acid than the patients treated with allopurinol (128.1 and 328.5 mg.h/dl, respectively). 
V primerjalni študiji je bilo zdravilo Fasturtec učinkovitejše od alopurinola: v prvih 96 urah po zdravljenju so bolniki, ki so se zdravili z zdravilom Fasturtec, imeli nižje povprečne koncentracije sečne kisline v krvi kot bolniki, ki so se zdravili z alopurinolom (128,1 oziroma 328,5 mg h/dl).
Fasturtec must not be used in patients with a deficiency in (low levels of) glucose 6 phosphate dehydrogenase (G6PD) or other metabolic disorders known to cause haemolytic anaemia (low haemoglobin levels caused by the abnormal breakdown of red blood cells). 
Zdravila Fasturtec ne smejo uporabljati bolniki s pomanjkanjem (nizkimi koncentracijami) glukoza-6fosfat dehidrogenaze (G6PD) ali drugimi presnovnimi motnjami, za katere je znano, da povzročajo hemolitično anemijo (nizko število rdečih krvničk, ki je posledica neobičajnega razkroja rdečih krvničk).
What is the risk associated with Fasturtec? 
Kakšna tveganja so povezana z zdravilom Fasturtec?
The enzyme was originally extracted from a fungus, but in Fasturtec it is produced by a method known as ‘recombinant DNA technology': it is made by a yeast into which a gene (DNA) has been introduced that makes it able to produce urate oxidase. 
Encim so prvotno pridobivali iz glive, pri zdravilu Fasturtec pa se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri se v kvasovko vstavi gen (DNK), s katerim lahko tvori urat oksidazo.
An additional study looked at the effects of Fasturtec in 21 children (aged between 6 months and 16 years) with blood cancers of whom 62% had uric acid levels that were too high. 
V drugi študiji so proučevali učinke zdravila Fasturtec pri 21 otrocih (starih od šest mesecev do 16 let) s krvnim rakom, pri čemer jih je 62 % imelo povišane koncentracije sečne kisline.
Patients undergoing chemotherapy may be at risk of rapid tumour lysis, where many cancer cells are broken down at once causing a sudden rise of uric acid in the blood which can cause damage to the kidneys. 
Bolniki, ki prejemajo kemoterapijo, so lahko izpostavljeni tveganju za hiter razkroj tumorja, pri čemer se veliko rakavih celic razgradi naenkrat, kar povzroči nenadno povečanje sečne količine v krvi, ki lahko poškoduje ledvice.
Why has Fasturtec been approved? 
Zakaj je bilo zdravilo Fasturtec odobreno?
The dose-finding studies showed that, after 48 hours, Fasturtec at a daily dose of 0.2 mg per kg reduced the uric acid levels to normal in 95% of patients. 
Študije, v katerih so skušali ugotoviti najustreznejši odmerek, so pokazale, da je zdravilo Fasturtec v dnevnem odmerku 0,2 mg na kg po 48 urah koncentracije sečne kisline zmanjšalo na normalne vrednosti pri 95 % bolnikov.
This helps to reduce the levels of uric acid in the blood, thereby reducing the load on the kidney and preventing any damage. 
To pomaga pri zniževanju koncentracije sečne kisline v krvi in zato zmanjša obremenitev ledvic in njihovo okvaro.
For the full list of all side effects reported with Fasturtec, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Fasturtec, glejte navodilo za uporabo.
It is available as a powder and solvent that are made up into a solution for infusion (drip) into a vein. 
Na voljo je v obliki praška in vehikla za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Fasturtec is used to treat and prevent high levels of uric acid in the blood in order to prevent kidney failure. 
Zdravilo Fasturtec se uporablja za zdravljenje in preprečevanje povečane koncentracije sečne kisline v krvi, da se prepreči odpoved delovanja ledvic.
Fasturtec is a medicine that contains the active substance rasburicase. 
Fasturtec je zdravilo, ki vsebuje zdravilno učinkovino razburikazo.
In the additional study, none of the 21 children treated with Fasturtec had high uric acid levels after 24 or 48 hours. 
V dodatni študiji se pri nobenem od 21 otrok, ki so bili zdravljeni z zdravilom Fasturtec, po 24 oziroma 48 urah niso pojavile povišane koncentracije sečne kisline.